首页> 美国卫生研究院文献>Genome Medicine >Variants of uncertain significance in BRCA: a harbinger of ethical and policy issues to come?
【2h】

Variants of uncertain significance in BRCA: a harbinger of ethical and policy issues to come?

机译:在BRCA中意义不确定的变量:即将出现的道德和政策问题的预兆吗?

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

After two decades of genetic testing and research, the BRCA1 and BRCA2 genes are two of the most well-characterized genes in the human genome. As a result, variants of uncertain significance (VUS; also called variants of unknown significance) are reported less frequently than for genes that have been less thoroughly studied. However, VUS continue to be uncovered, even for BRCA1/2. The increasing use of multi-gene panels and whole-genome and whole-exome sequencing will lead to higher rates of VUS detection because more genes are being tested, and most genomic loci have been far less intensively characterized than BRCA1/2. In this article, we draw attention to ethical and policy-related issues that will emerge. Experience garnered from BRCA1/2 testing is a useful introduction to the challenges of detecting VUS in other genetic testing contexts, while features unique to BRCA1/2 suggest key differences between the BRCA experience and the current challenges of multi-gene panels in clinical care. We propose lines of research and policy development, emphasizing the importance of pooling data into a centralized open-access database for the storage of gene variants to improve VUS interpretation. In addition, establishing ethical norms and regulated practices for sharing and curating data, analytical algorithms, interpretive frameworks and patient re-contact are important policy areas.Electronic supplementary materialThe online version of this article (doi:10.1186/s13073-014-0121-3) contains supplementary material, which is available to authorized users.
机译:经过二十多年的基因测试和研究,BRCA1和BRCA2基因是人类基因组中最典型的两个基因。结果,与尚未进行充分研究的基因相比,报道不确定性显着的变体(VUS;也称为未知意义的变体)的频率更低。但是,即使对于BRCA1 / 2,VUS仍然被发现。多基因面板和全基因组和全外显子测序的使用越来越多,这将导致VUS检测率更高,因为正在测试更多的基因,而且大多数基因组位点的特征强度远低于BRCA1 / 2。在本文中,我们提请您注意即将出现的与道德和政策相关的问题。从BR​​CA1 / 2测试中获得的经验是对其他基因测试背景下检测VUS挑战的有用介绍,而BRCA1 / 2独有的功能表明BRCA经验与当前多基因专家组在临床护理中的挑战之间存在关键差异。我们建议进行研究和制定政策,强调将数据汇总到中央开放访问数据库中以存储基因变体以改善VUS解释的重要性。此外,建立共享和管理数据的道德规范和规范做法,分析算法,解释框架和患者重新联系也是重要的政策领域。电子补充材料本文的在线版本(doi:10.1186 / s13073-014-0121-3 )包含补充材料,授权用户可以使用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号